Metabolite Card
Formula: C4H9NO2 (103.0633)
SMILES: C[C@@H](CN)C(O)=O
Synonyms [en]
(S)-3-Amino-2-methylpropanoate; (S)-3-aminoisobutyric acid; (S)-3-Amino-isobutyric acid; (S)-beta-aminoisobutyrate; (S)-3-Amino-isobutanoic acid; L-3-Amino-isobutanoic acid
Last reviewed on 2024-06-28.
Cite this Page
L-3-Aminoisobutanoate. 数据之源,洞见之始. SMRUCC genomics institute, a synthetic life researcher from China.
https://biocad_registry.innovation.ac.cn/s/(-)-arctiin
(retrieved
2026-01-03) (CAD Registry RN: BioCAD00000012917). Licensed
under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).
Note
beta-Aminoisobutyric acid is a non-protein amino acid originating from the catabolism of thymine and valine. The concentration of beta-aminoisobutyric acid is normally low in urine as beta-aminoisobutyric acid is further catabolized by beta-aminoisobutyrate aminotransferases to methylmalonic acid semialdehyde and propionyl-CoA. beta-Aminoisobutyric acid occurs in two isomeric forms and both enantiomers of beta-aminoisobutyric acid can be detected in human urine and plasma. In plasma, the S-enantiomer is the predominant type due to active renal reabsorption. In contrast, urine almost exclusively contains the R-enantiomer of beta-aminoisobutyric acid, which is eliminated both by filtration and tubular secretion. Persistently increased levels of beta-aminoisobutyric acid have been observed in individuals with a deficiency of R (-)-beta-aminoisobutyrate-pyruvate aminotransferase. In addition, transient high levels of beta-aminoisobutyric acid have been observed under a variety of pathological conditions such as lead poisoning, starvation, in total body irradiation, and in a number of malignancies. The S-enantiomer of beta-aminoisobutyric acid is predominantly derived from the catabolism of valine. It has been suggested that altered homeostasis of beta-alanine underlies some of the clinical abnormalities encountered in patients with a dihydropyrimidine dehydrogenase (DPD) deficiency. DPD constitutes the first step of the pyrimidine degradation pathway, in which the pyrimidine bases uracil and thymine are catabolized to beta-alanine and the R-enantiomer of beta-aminoisobutyric acid respectively. In normal individuals with an intact pyrimidine degradation pathway, R-methylmalonic acid semialdehyde can be synthesized directly from the catabolism of thymine. Hence, there might be less cross-over between the valine and thymine pathway, allowing the conversion of S-methylmalonic acid semialdehyde into S-beta-aminoisobutyric acid and the subsequent accumulation of S-beta-aminoisobutyric acid in plasma (PMID: 14705962, 14292857, 14453202).
DBLinks
- CAS Registry Number: 4249-19-8
- PubChem CID: 439434
- ChEBI: 18188
- HMDB: HMDB0002166
- LipidMaps: LMFA01100050
- KEGG: C03284
- BioCyc: CPD-466
- NCBI MeSH:
- Wikipedia:
Other DBLinks
- CAS Registry Number: 4249-19-8
- PubChem: 439434
- ChEBI: ChEBI:18188
- ChEBI: ChEBI:33094
- HMDB: HMDB0002166
- LipidMaps: LMFA01100050
- KEGG: C03284
- BioCyc: CPD-466
- DrugBank: DB03432
- RefMet: RM0134977
- Metlin: METLIN_45884
Class / Ontology
- WishartLab ClassyFire: [Amino acids, peptides, and analogues] Amino acids, peptides, and analogues
- RefMet: [Amino acids] Amino acids
- LipidMaps: [Amino fatty acids [FA0110]] Amino fatty acids [FA0110]
- ChEBI: [CHEBI:33094] (S)-3-aminoisobutyric acid
| ID | EC Number | Name |
|---|---|---|
| KEGG:R04187 | 2.6.1.18 | L-alanine:3-oxopropanoate aminotransferase |
| KEGG:R04188 | 2.6.1.22 | L-3-amino-isobutanoate:2-oxoglutarate aminotransferase |
| BioCyc:RXN-14265 | 2.6.1.- | L-alanine-(S)-methylmalonate semialdehyde aminotransferase |
| BioCyc:2.6.1.22-RXN | 2.6.1.22 | 2-KETOGLUTARATE + CPD-466<=>GLT + CH3-MALONATE-S-ALD |
Taxonomy Source
Pathway Synthetic
| pathway id | name |
|---|---|
| WikiPathways:WP3604 | Biochemical pathways: part I |
| PathBank:SMP0120662 | 3-Methylcrotonyl-CoA Carboxylase Deficiency Type I |
| PathBank:SMP0120806 | 3-Hydroxyisobutyric Aciduria |
| PathBank:SMP0120440 | 3-Hydroxy-3-methylglutaryl-CoA Lyase Deficiency |
| PathBank:SMP0120444 | 3-Methylglutaconic Aciduria Type IV |
| PathBank:SMP0120516 | Maple Syrup Urine Disease |
| PathBank:SMP0120589 | Isovaleric Acidemia |
| PathBank:SMP0000032 | Valine, Leucine, and Isoleucine Degradation |
| PathBank:SMP0000173 | beta-Ketothiolase Deficiency |
| PathBank:SMP0000199 | Maple Syrup Urine Disease |
| PathBank:SMP0000384 | Methylmalonate Semialdehyde Dehydrogenase Deficiency |
| PathBank:SMP0000141 | 3-Methylglutaconic Aciduria Type IV |
| PathBank:SMP0000524 | Isovaleric Acidemia |
| PathBank:SMP0087234 | Valine, Leucine, and Isoleucine Degradation |
| PathBank:SMP0120661 | 3-Hydroxy-3-methylglutaryl-CoA Lyase Deficiency |
| PathBank:SMP0120665 | 3-Methylglutaconic Aciduria Type IV |
| PathBank:SMP0120745 | Methylmalonic Aciduria |
| PathBank:SMP0120757 | Propionic Acidemia |
| PathBank:SMP0120805 | 3-Hydroxyisobutyric Acid Dehydrogenase Deficiency |
| PathBank:SMP0120439 | 2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency |